ストックスクリーナーアプリを入手
458.73
1.74%
8.045
前日終値:
$450.68
開ける：
$451
24時間の取引高:
356.34K
Relative Volume:
0.32
時価総額：
$60.13B
収益：
$2.46B
当期純損益:
$-319.09M
株価収益率:
-185.95
EPS:
-2.4669
ネットキャッシュフロー:
$-52.09M
1週間 パフォーマンス:
-0.53%
1か月 パフォーマンス:
-4.89%
6か月 パフォーマンス:
+88.49%
1年 パフォーマンス:
+69.26%
1日の値動き範囲:
$448.83
$459.57
1週間の範囲:
$448.47
$465.00
52週間の値動き範囲:
$205.87
$484.21
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
名前
Alnylam Pharmaceuticals Inc
セクター
電話
(617) 551-8200
住所
675 WEST KENDALL STREET, CAMBRIDGE, MA
ALNY を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALNY
Alnylam Pharmaceuticals Inc
|
458.73 | 59.07B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.26 | 107.98B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.57 | 59.76B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
804.51 | 49.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
337.29 | 38.56B | 4.56B | -176.77M | 225.30M | -1.7177 |
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-04 | アップグレード | Oppenheimer | Perform → Outperform |
| 2025-08-04 | アップグレード | Wolfe Research | Underperform → Peer Perform |
| 2025-07-30 | 再開されました | Raymond James | Outperform |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-03-31 | 開始されました | Redburn Atlantic | Buy |
| 2025-03-24 | アップグレード | JP Morgan | Neutral → Overweight |
| 2024-11-12 | ダウングレード | Wolfe Research | Peer Perform → Underperform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-08-16 | アップグレード | Goldman | Neutral → Buy |
| 2024-02-16 | ダウングレード | Goldman | Buy → Neutral |
| 2024-02-15 | 開始されました | Wolfe Research | Peer Perform |
| 2023-12-08 | 開始されました | Wells Fargo | Equal Weight |
| 2023-10-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 開始されました | Raymond James | Outperform |
| 2023-05-05 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 開始されました | SMBC Nikko | Neutral |
| 2023-03-21 | 開始されました | Bernstein | Outperform |
| 2023-01-18 | 開始されました | Canaccord Genuity | Buy |
| 2022-09-09 | 再開されました | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-06-27 | ダウングレード | Guggenheim | Buy → Neutral |
| 2022-06-07 | 開始されました | William Blair | Outperform |
| 2022-04-25 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 開始されました | Citigroup | Buy |
| 2022-02-03 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-01-03 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | アップグレード | Goldman | Neutral → Buy |
| 2021-11-22 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | アップグレード | Oppenheimer | Perform → Outperform |
| 2021-10-04 | アップグレード | UBS | Neutral → Buy |
| 2021-08-04 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | ダウングレード | Guggenheim | Buy → Neutral |
| 2021-02-12 | ダウングレード | Citigroup | Buy → Neutral |
| 2021-02-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2021-01-25 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 再開されました | Berenberg | Hold |
| 2020-09-08 | 開始されました | Citigroup | Buy |
| 2020-08-11 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 再開されました | Evercore ISI | Outperform |
| 2020-03-19 | 開始されました | Berenberg | Buy |
| 2019-12-19 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-11-20 | 開始されました | Oppenheimer | Outperform |
| 2019-11-13 | 開始されました | BofA/Merrill | Buy |
| 2019-05-23 | 再開されました | Goldman | Neutral |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-03-06 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-03-05 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 開始されました | UBS | Neutral |
| 2018-10-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 繰り返されました | Stifel | Buy |
| 2018-08-07 | アップグレード | Stifel | Hold → Buy |
| 2018-05-04 | 繰り返されました | Stifel | Hold |
| 2018-03-28 | 開始されました | Evercore ISI | In-line |
すべてを表示
Alnylam Pharmaceuticals Inc (ALNY) 最新ニュース
KLP Kapitalforvaltning AS Has $16.01 Million Stock Position in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Shell Asset Management Co. Purchases 1,602 Shares of Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
What earnings revisions data tells us about Alnylam Pharmaceuticals Inc.Price Action & Expert Curated Trade Ideas - newser.com
Weiss Ratings Reaffirms "Sell (D-)" Rating for Alnylam Pharmaceuticals (NASDAQ:ALNY) - MarketBeat
Alnylam’s AMVUTTRA Reduces GI Events in ATTR-CM Patients, According to New HELIOS-B Data - MSN
Amyloidosis Clinical Market Outlook 2024-2034: Expanding Diagnostic Capabilities - openPR.com
27 Analysts Assess Alnylam Pharmaceuticals: What You Need To Know - Benzinga
Did Amvuttra’s Phase 3 Update and ZENITH Trial Milestone Just Shift Alnylam’s (ALNY) Investment Narrative? - simplywall.st
Alnylam Pharmaceuticals (ALNY) Gets Target Price Boost from Morgan Stanley | ALNY Stock News - GuruFocus
Morgan Stanley Raises Alnylam Pharmaceuticals (NASDAQ:ALNY) Price Target to $475.00 - MarketBeat
Stifel Raises Price Target for ALNY; Maintains 'Buy' Rating | AL - GuruFocus
Smart tools for monitoring Alnylam Pharmaceuticals Inc.’s price action2025 Bull vs Bear & Short-Term Trading Alerts - newser.com
Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $495.00 Price Target at Stifel Nicolaus - MarketBeat
Morgan Stanley Raises Price Target on Alnylam Pharmaceuticals to $475 From $405, Keeps Equalweight Rating - MarketScreener
Is Alnylam Pharmaceuticals Inc. (DUL) stock a top hedge fund pickWeekly Investment Recap & Smart Money Movement Tracker - newser.com
News impact scoring models applied to Alnylam Pharmaceuticals Inc.Forecast Cut & Free Weekly Chart Analysis and Trade Guides - newser.com
Is Alnylam Pharmaceuticals Inc a good long term investmentStraddle and Strangle Trades & Superior Wealth Growth - earlytimes.in
Is Alnylam Pharmaceuticals Inc DUL a good long term investmentGlobal Trade Effects & Build Wealth Brick by Brick With Us - earlytimes.in
Will Alnylam Pharmaceuticals Inc. (DUL) stock announce special dividendWeekly Loss Report & Accurate Intraday Trading Signals - newser.com
What indicators show strength in Alnylam Pharmaceuticals Inc.Quarterly Profit Report & Advanced Swing Trade Entry Alerts - newser.com
Is Alnylam Pharmaceuticals Inc. (DUL) stock attractive for dividend growth2025 Winners & Losers & Risk Managed Investment Strategies - newser.com
Is Alnylam Pharmaceuticals Inc. stock ready for breakout2025 Trade Ideas & High Win Rate Trade Tips - newser.com
Alnylam Pharmaceuticals (ALNY): Assessing Valuation After ZENITH Phase 3 Trial Launch and HELIOS-B Data Reveal - simplywall.st
Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Set To Breakeven - Yahoo Finance
AMF Tjanstepension AB Makes New $10.61 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Robeco Institutional Asset Management B.V. Trims Holdings in Alnylam Pharmaceuticals, Inc. $ALNY - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) Upgraded to Strong-Buy at Wall Street Zen - Defense World
Kevin Joseph Fitzgerald Sells 2,441 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) CEO Sells $4,034,094.20 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,364,372.56 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Sells $1,727,283.05 in Stock - MarketBeat
Alnylam Pharmaceuticals (NASDAQ:ALNY) EVP Tolga Tanguler Sells 1,405 Shares - MarketBeat
Alnylam Pharma Secures $500M Credit Agreement - TipRanks
Alnylam Pharmaceuticals says on Sept 30, entered into credit agreement with Bank of AmericaSEC filing - MarketScreener
With Emma Walmsley exiting GSK, who will be pharma’s top women CEOs? - PharmaVoice
Alnylam Pharmaceuticals, Inc. $ALNY Shares Sold by J. Safra Sarasin Holding AG - MarketBeat
Does Alnylam Pharmaceuticals Inc. show high probability of rebound2025 Sector Review & Growth Focused Stock Pick Reports - newser.com
8,322 Shares in Alnylam Pharmaceuticals, Inc. $ALNY Purchased by Lbp Am Sa - MarketBeat
Is Alnylam Pharmaceuticals Inc. (DUL) stock overpriced at current multiplesJuly 2025 Sentiment & Fast Momentum Entry Tips - newser.com
Alnylam downgraded at Wolfe on doubts over Amvuttra growth - MSN
Alnylam (ALNY) Reports 238% Growth in Amvuttra Since February Launch, RBC Raises Price Target - Yahoo Finance
Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots - Bloomberg.com
Alnylam Pharmaceuticals (ALNY) Pulls Ad After FDA Warning - GuruFocus
Alnylam yanks Amvuttra TV ad following FDA letterreport - Seeking Alpha
Cambridge-based Alnylam Pharmaceuticals pulls TV ad after Trump crackdown on drug industry spots - The Boston Globe
Alnylam pulls heart drug TV ad amid FDA crackdown - Investing.com
Wealth Enhancement Slashes Alnylam Pharmaceuticals, Inc. (ALNY) Stake by 64.5% - MSN
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran - BioSpace
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra? - Yahoo Finance
Alnylam Pharmaceuticals Inc (ALNY) 財務データ
収益
当期純利益
現金流量
EPS
0.66%
3.96%
大文字化:
|
ボリューム (24 時間):